2-(4-((2,6-difluoro-4-(pyrimidin-5-yl)phenoxy)methyl)piperidin-1-yl)-5-ethylpyrimidine | 1204129-09-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 2-(4-((2,6-difluoro-4-(pyrimidin-5-yl)phenoxy)methyl)piperidin-1-yl)-5-ethylpyrimidine
• 英文别名: 2-[4-[(2,6-Difluoro-4-pyrimidin-5-ylphenoxy)methyl]piperidin-1-yl]-5-ethylpyrimidine
• CAS: 1204129-09-8
• 化学式: C₂₂H₂₃F₂N₅O
• 分子量: 411.454
• InChiKey: LZRJPDMDTZXEBP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  30
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  64
• 氢给体数：
  0
• 氢受体数：
  8

文献信息

• [EN] 4-PHENOXYMETHYLPIPERIDINES AS MODULATORS OF GPR119 ACTIVITY<br/>[FR] 4-PHÉNOXYMÉTHYLPIPÉRIDINES COMME MODULATEURS DE L'ACTIVITÉ DE GPR119
  申请人：IRM LLC

  公开号：WO2010006191A1

  公开（公告）日：2010-01-14

  The present invention provides compounds of Formula I, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent; diseases or disorders associated with the activity of GPR119.

  本发明提供了一种具有I式化合物的药物组合物，以及使用这种化合物来治疗或预防与GPR119活性相关的疾病或紊乱的方法。
• 4-PHENOXYMETHYLPIPERIDINES AS MODULATORS OF GPR119 ACTIVITY
  申请人：Epple Robert

  公开号：US20110190298A1

  公开（公告）日：2011-08-04

  The present invention provides compounds of Formula I, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent; diseases or disorders associated with the activity of GPR119.

  本发明提供了一种I型化合物，包括这种化合物的药物组合物以及使用这种化合物治疗或预防与GPR119活性相关的疾病或疾病的方法。
• GLUCAGON SUPERFAMILY PEPTIDES EXHIBITING G PROTEIN-COUPLED RECEPTOR ACTIVITY
  申请人：Indiana University Research and Technology Corporation

  公开号：EP2568993A1

  公开（公告）日：2013-03-20
• JP2011527701A
  申请人：——

  公开号：JP2011527701A

  公开（公告）日：2011-11-04
• GLUCAGON SUPERFAMILY PEPTIDES EXHBITING G PROTEIN COUPLED RECEPTOR ACTIVITY
  申请人：Dimarchi Richard D.

  公开号：US20130116172A1

  公开（公告）日：2013-05-09

  Provided herein are glucagon superfamily peptides conjugated with GPCR ligands that are capable of acting at a G protein-coupled receptor. Also provided herein are pharmaceutical compositions and kits of the conjugates of the invention. Further provided herein are methods of treating a disease, e.g., a metabolic disorder, such as diabetes and obesity, comprising administering the conjugates of the invention.